AlloVir is a leading company in the development of novel cell therapies, with a focus on restoring and fighting viral infections. Founded in 2013, AlloVir, formerly known as ViraCyte, specializes in the creation of allogeneic, off-the-shelf virus-specific T-cell therapies (VSTs). These therapies are designed to treat or prevent severe viral infections and diseases in patients with T-cell deficiencies. AlloVir's innovative approach aims to provide effective solutions for patients with limited or compromised immune systems.

No photo description available. Work. Allovir, inc, profile picture · Allovir, inc. Payroll and Benefits Manger. March 18, 2021 - Present. Brooks Automation ...

AlloVir is pleased to announce that data from our Phase 2 #clinicaltrial evaluating our lead virus-specific T #celltherapy, Posoleucel, as a treatment for BK ...

AlloVir, formerly ViraCyte, was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring ...

AlloVir

Find contacts at this company